| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Samuel Keit. Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness. Expert review of neurotherapeutics. vol 9. issue 1. 2009-03-03. PMID:19102665. |
this article discusses the efficacy, tolerability and cost-effectiveness of long-acting risperidone in schizophrenia and bipolar disorder patients, and suggests possibilities for how its role in clinical practice may change over the next 5 years. |
2009-03-03 |
2023-08-12 |
Not clear |
| Margret S H Harris, Courtney L Wiseman, James L Reilly, Matcheri S Keshavan, John A Sweene. Effects of risperidone on procedural learning in antipsychotic-naive first-episode schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 34. issue 2. 2009-02-23. PMID:18536701. |
effects of risperidone on procedural learning in antipsychotic-naive first-episode schizophrenia. |
2009-02-23 |
2023-08-12 |
Not clear |
| Masashi Ikeda, Yoshio Yamanouchi, Yoko Kinoshita, Tsuyoshi Kitajima, Reiji Yoshimura, Shuji Hashimoto, Michael C O'Donovan, Jun Nakamura, Norio Ozaki, Nakao Iwat. Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics. vol 9. issue 10. 2009-02-13. PMID:18855532. |
variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. |
2009-02-13 |
2023-08-12 |
Not clear |
| Masashi Ikeda, Yoshio Yamanouchi, Yoko Kinoshita, Tsuyoshi Kitajima, Reiji Yoshimura, Shuji Hashimoto, Michael C O'Donovan, Jun Nakamura, Norio Ozaki, Nakao Iwat. Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics. vol 9. issue 10. 2009-02-13. PMID:18855532. |
we conducted a pharmacogenetic study to evaluate whether variants in dopamine-related genes (drd1-drd5, akt1 and gsk3beta) and serotonin receptor genes (htr1a, htr1b, htr1d, htr2a, htr2c, htr6 and htr7) can be used to predict the efficacy of risperidone treatment for schizophrenia. |
2009-02-13 |
2023-08-12 |
Not clear |
| A Jone. What are the nursing implications when using paliperidone prolonged release for people with schizophrenia. Journal of psychiatric and mental health nursing. vol 15. issue 10. 2009-02-13. PMID:19012670. |
it is the active metabolite of risperidone, a drug that has been successfully used in the treatment of schizophrenia and mood disorder. |
2009-02-13 |
2023-08-12 |
Not clear |
| Qi Chen, Zhuo-Ji Cai, Pei-Xian Mao, Yi-Ming Zhai, Philip B Mitchell, Yi-Lang Tan. Effects of risperidone on glucose metabolism in Chinese patients with schizophrenia: a prospective study. Journal of psychiatric research. vol 43. issue 2. 2009-02-12. PMID:18423490. |
effects of risperidone on glucose metabolism in chinese patients with schizophrenia: a prospective study. |
2009-02-12 |
2023-08-12 |
Not clear |
| Qi Chen, Zhuo-Ji Cai, Pei-Xian Mao, Yi-Ming Zhai, Philip B Mitchell, Yi-Lang Tan. Effects of risperidone on glucose metabolism in Chinese patients with schizophrenia: a prospective study. Journal of psychiatric research. vol 43. issue 2. 2009-02-12. PMID:18423490. |
this study aimed to explore the effect of risperidone on the glucose-regulating mechanism of patients with schizophrenia by using the oral glucose tolerance test (ogtt), measuring insulin and c-peptide levels. |
2009-02-12 |
2023-08-12 |
Not clear |
| J Cordes, A Sinha-Röder, K G Kahl, J Malevani, J Thuenker, C Lange-Asschenfeldt, H Hauner, M W Agelink, A Klimk. [Therapeutic options for weight management in schizophrenic patients treated with atypical antipsychotics]. Fortschritte der Neurologie-Psychiatrie. vol 76. issue 12. 2009-02-09. PMID:18924059. |
extensive, selective literature review of 2500 articles from the last years (up to december 2007) predominantly from medline and cochrane, using as search terms "antipsychotic or schizophrenia or individual drug names (amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, ziprasidone)" and the terms "bmi, weight gain, metabolic syndrome, diabetes, lipid(s), cholesterol, triglycerides" was conducted. |
2009-02-09 |
2023-08-12 |
Not clear |
| Atheir Abbas, Bryan L Rot. Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. Expert opinion on pharmacotherapy. vol 9. issue 18. 2009-02-06. PMID:19040345. |
pimavanserin tartrate is the first 5-ht(2a) inverse agonist to enter clinical trials as a treatment for l-dopa-induced psychosis in parkinson's disease and for augmentation of low-dose risperidone treatment in schizophrenia. |
2009-02-06 |
2023-08-12 |
Not clear |
| R V Akhapki. [The study of therapeutic efficacy of two forms of risperidone--rileptid and rispolept in patients with schizophrenia]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 108. issue 8. 2009-02-03. PMID:18833105. |
[the study of therapeutic efficacy of two forms of risperidone--rileptid and rispolept in patients with schizophrenia]. |
2009-02-03 |
2023-08-12 |
Not clear |
| Robin Emsley, Petrus Oosthuizen, Liezl Koen, Dana J H Niehaus, Rossella Medori, Jonathan Rabinowit. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. International clinical psychopharmacology. vol 23. issue 6. 2009-01-22. PMID:18854720. |
remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. |
2009-01-22 |
2023-08-12 |
Not clear |
| Robin Emsley, Petrus Oosthuizen, Liezl Koen, Dana J H Niehaus, Rossella Medori, Jonathan Rabinowit. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. International clinical psychopharmacology. vol 23. issue 6. 2009-01-22. PMID:18854720. |
we assessed rates, predictors, and correlates of remission in a sample of patients with first-episode schizophrenia treated with injectable, long-acting risperidone. |
2009-01-22 |
2023-08-12 |
Not clear |
| Robin Emsley, Petrus Oosthuizen, Liezl Koen, Dana J H Niehaus, Rossella Medori, Jonathan Rabinowit. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. International clinical psychopharmacology. vol 23. issue 6. 2009-01-22. PMID:18854720. |
this was a single-site open-label study in which 50 newly diagnosed cases of schizophreniform disorder or schizophrenia aged 16 to 43 years were treated with injectable, long-acting risperidone 25-50 mg every 2 weeks for 2 years. |
2009-01-22 |
2023-08-12 |
Not clear |
| José M Olivares, Alfonso Rodriguez-Martinez, José A Burón, David Alonso-Escolano, Alexander Rodriguez-Morale. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain. Applied health economics and health policy. vol 6. issue 1. 2009-01-14. PMID:18774869. |
cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-star database in spain. |
2009-01-14 |
2023-08-12 |
Not clear |
| José M Olivares, Alfonso Rodriguez-Martinez, José A Burón, David Alonso-Escolano, Alexander Rodriguez-Morale. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain. Applied health economics and health policy. vol 6. issue 1. 2009-01-14. PMID:18774869. |
the availability of long-acting injectable risperidone may increase adherence to antipsychotic treatment and lead to improved clinical and economic outcomes for patients with schizophrenia. |
2009-01-14 |
2023-08-12 |
Not clear |
| L Wang, C Fang, A Zhang, J Du, L Yu, J Ma, G Feng, Q Xing, L H. The --1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients. Journal of psychopharmacology (Oxford, England). vol 22. issue 8. 2009-01-13. PMID:18308786. |
the --1019 c/g polymorphism of the 5-ht(1)a receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients. |
2009-01-13 |
2023-08-12 |
Not clear |
| Barbora Tislerova, Martin Brunovsky, Jiri Horacek, Tomas Novak, Miloslav Kopecek, Pavel Mohr, Vladimír Krajc. LORETA functional imaging in antipsychotic-naive and olanzapine-, clozapine- and risperidone-treated patients with schizophrenia. Neuropsychobiology. vol 58. issue 1. 2009-01-13. PMID:18781085. |
we included 41 subjects with schizophrenia (antipsychotic naive = 11; clozapine = 8; olanzapine = 10; risperidone = 12) and 20 healthy controls. |
2009-01-13 |
2023-08-12 |
human |
| Herbert Y Meltzer, Tomiki Sumiyosh. Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia? Behavioural brain research. vol 195. issue 1. 2009-01-12. PMID:18707769. |
aripiprazole, clozapine, olanzapine, perospirone, quetiapine risperidone, and ziprasidone are examples of atypical antipsychotic drugs which are either direct or indirect 5-ht(1a) agonists which have been shown to improve cognitive function in patients with schizophrenia. |
2009-01-12 |
2023-08-12 |
Not clear |
| Jehan Marino, Joshua Caballer. Paliperidone extended-release for the treatment of schizophrenia. Pharmacotherapy. vol 28. issue 10. 2009-01-08. PMID:18823223. |
paliperidone, the major active metabolite of risperidone (9-hydroxyrisperidone), is a second-generation antipsychotic that was recently approved by the united states food and drug administration for treatment of acute schizophrenia and for maintenance treatment of schizophrenia. |
2009-01-08 |
2023-08-12 |
Not clear |
| Sofie A M K Houthoofd, Manuel Morrens, Bernard G C Sabb. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder. Clinical therapeutics. vol 30. issue 9. 2009-01-06. PMID:18840365. |
cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder. |
2009-01-06 |
2023-08-12 |
Not clear |